Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.54 |
| ▸ | SELP | P16109 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | METAP2 | P50579 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20626555 | 1.00 | L3MBTL1 (0.54) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL535106 | 1.00 | L3MBTL1 (0.54) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL9110670 | 1.00 | L3MBTL1 (0.54) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL15196691 | 1.00 | L3MBTL1 (0.54) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL13308242 | 0.93 | L3MBTL1 (0.47) | L3MBTL1SELPKMT2AMEN1ALDH1A1 | |
| SCHEMBL26492359 | 0.91 | L3MBTL1 (0.50) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL9112774 | 0.90 | L3MBTL1 (0.50) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL535845 | 0.90 | L3MBTL1 (0.50) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL19614247 | 0.90 | L3MBTL1 (0.50) | L3MBTL1SELPKMT2AMEN1BCHE | |
| SCHEMBL19614246 | 0.90 | L3MBTL1 (0.50) | L3MBTL1SELPKMT2AMEN1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340822-B2 | Methods of diagnosing a disease and methods of monitoring treatment of a disease by quantifying a non-reducing end glycan residual compound and comparing to a second biomarker | BIOMARIN PHARMACEUTICAL INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20160060365-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. | 2016-03-03 | — | — | US | disclosed |
| US-20140356855-A1 | METHODS OF DIAGNOSING A DISEASE AND METHODS OF MONITORING TREATMENT OF A DISEASE BY QUANTIFYING A NON-REDUCING END GLYCAN RESIDUAL COMPOUND AND COMPARING TO A SECOND BIOMARKER | BIOMARIN PHARM INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-20120142560-A1 | HEPARAN SULFATE SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060365-A1 | HEPARAN SULFATE SYNTHESIS | HPSE, STT3B, DDOST | L3MBTL1 3217/4885SELP 682/4885KMT2A 2909/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.